Clearside Biomedical

Clearside Biomedical Cash Conversion Cycle

Delisted

The Cash Conversion Cycle (CCC) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -3,445.70. In the previous year, Cash Conversion Cycle (CCC) was -2,259.57 — a change of 52.49% (lower).

Cash Conversion Cycle

-3,445.70

YoY

52.49%

Last updated:

Cash Conversion Cycle (CCC) of Clearside Biomedical is 2024 -3,445.70 . Cash Conversion Cycle (CCC) of Clearside Biomedical was 2023 -2,259.57 . It decreases by 52.49% lower compared to the previous year.

The Clearside Biomedical Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2021
123.39 USD
Jan 1, 2022
-1,916.25 USD
Jan 1, 2023
-2,259.57 USD
Jan 1, 2024
-3,445.70 USD
The Clearside Biomedical Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-3,445.70+52.49%
-2,259.57+17.92%
-1,916.25-1,652.95%
123.39—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Cash Conversion Cycle (CCC) of Clearside Biomedical is -3,445.70 in 2024.

Cash Conversion Cycle (CCC) of Clearside Biomedical changed from -2,259.57 to -3,445.70, representing a 52.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clearside Biomedical

All Key Metrics — Clearside Biomedical